Clinical trials: Mucinous Adenocarcinoma
Adenocarcinoma of the Rectum, Adenocarcinoma
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
The aim of this study is to determine whether greater rectal cancer downstaging and regression occurs when surgery is delayed to 12 weeks after completion of radiotherapy/chemotherapy compared to 6 weeks.
- Conditions
- Adenocarcinoma of the Rectum, Adenocarcinoma, Adenocarcinoma, Mucinous, Carcinoma
- Trial name
- NCT01037049
- Testing
- Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
- Where
- 23 sites in Brazil, Canada and 2 more
- Volunteers
- 237 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in…
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01013649
- Testing
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine
- Where
- 689 sites in United States, Belgium and 2 more
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Carcinoma, Cancer
Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies
This original research investigates the critical issue of gastrointestinal (GI) second primary malignancies (SPMs) in patients with signet ring cell carcinoma (SRCC), a rare and aggressive subtype of colorectal cancer.
- Conditions
- Colorectal Carcinoma, Cancer, Signet Ring Adenocarcinoma of the Colon
- Trial name
- NCT06978595
- Where
- Egypt
- Volunteers
- 8,171 people
- Sponsor
- asmaa salama ibrahim
Pseudomyxoma Peritonei
Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant capecitabine and cyclophosphamide treatment in patients affected by huge Pseudomyxoma peritonei (PMP) (peritoneal cancer index >28).
- Trial name
- REVERSE (NCT06800391)
- Testing
- Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Ductal Adenocarcinoma, Intraductal Papillary Mucinous Neoplasm
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
The purpose of this Study is to assist in implementing a practical, easy-to-adopt lifestyle intervention that optimizes patient outcomes and minimizes pancreatic ductal adenocarcinoma (PDAC) risk.
- Trial name
- PANTHER-PIC (NCT06712797)
- Testing
- Physical Activity (PA), Nutrition (N)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fatigue, Malignant Ovarian Mixed Epithelial Tumor
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or…
- Conditions
- Fatigue, Malignant Ovarian Mixed Epithelial Tumor, Neuropathy, Neurotoxicity Syndrome
- Trial name
- NCT01492920
- Testing
- Acetyl-L-Carnitine Hydrochloride, Questionnaire Administration, Quality-of-Life Assessment
- Sponsor
- Gynecologic Oncology Group
Low Grade Serous Carcinoma
Ribociclib and Letrozole Treatment in Ovarian Cancer
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
- Trial name
- NCT03673124
- Testing
- Ribociclib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Ovarian Carcinoma
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- BEDOCA (NCT03150121)
- Testing
- Uterine lavage, Blood sample, Uterine lavage catheter
- Where
- 4 sites in Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon
Edrecolomab in Treating Patients With Stage II Colon Cancer
Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer, Stage IIB Colon Cancer
- Trial name
- NCT00002968
- Testing
- edrecolomab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2,100 people
- Sponsor
- National Cancer Institute (NCI)
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory).
- Conditions
- Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm
- Trial name
- NCT03108131
- Testing
- Atezolizumab, Cobimetinib
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Cancer Metastatic to the Peritoneal Cavity
Severe Neutropenia After HIPEC Using Mitomycin-C
Mitomycin-C (MMC) is the most commonly used chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) to treat colorectal cancer patients with peritoneal metastases.
- Conditions
- Colorectal Cancer Metastatic, Cancer Metastatic to the Peritoneal Cavity, Appendiceal Neoplasm, Pseudomyxoma Peritonei
- Trial name
- NCT05513183
- Testing
- Intraoperative blood and peritoneal fluid samplings during HIPEC
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Gangnam Severance Hospital
Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
The purpose of this study is to find the highest dose of a drug, samuraciclib, that can be given with standard of care chemotherapy (gemcitabine and nab-paclitaxel) without causing very severe side effects.
- Conditions
- Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous Carcinoma of the Pancreas
- Trial name
- SONIC (NCT07665684)
- Testing
- Samuraciclib + Gemcitabine & Nab-Paclitaxel
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- University Health Network, Toronto
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of combining gefitinib with fluorouracil, leucovorin, and irinotecan in treating patients who have advanced or recurrent colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
- Trial name
- NCT00052585
- Testing
- irinotecan hydrochloride, gefitinib, leucovorin calcium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Appendiceal Cancer, Appendiceal Adenocarcinoma
Molecular Profiling for Risk Stratification in Appendiceal Cancer
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort.
- Trial name
- NCT07587268
- Testing
- DNA Methylation Profiling, m6A Epitranscriptomic Profiling
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Uterine Serous Carcinoma
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
- Trial name
- NCT04814108
- Testing
- Azenosertib
- Where
- 56 sites in United States, Australia and 2 more
- Volunteers
- 92 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic…
- Trial name
- NCT00408590
- Testing
- carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
This phase II trial studies how well radiation therapy works in treating post-menopausal women with early stage breast cancer undergoing surgery. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01754519
- Testing
- Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Appendiceal Adenocarcinoma, Colorectal
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help…
- Trial name
- NCT05947838
- Testing
- Circulating tumoral DNA directed neoadjuvant therapy arm
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Metastasis, Colorectal Cancer
A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients
This prospective, multi-center, real-world study is conducted to investigate the impact of different treatment strategies (systemic chemotherapy combined with oophorectomy or with other local treatment or chemotherapy alone) on…
- Trial name
- proOMCRC (NCT04716257)
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- West China Hospital